Alembic Pharma surged over 12% after the US FDA approved its cancer drug, a generic version of Doxorubicin Hydrochloride Liposome injection. Analyst Sunil Kotak flagged a bullish chart breakout, supported by volume and RSI crossover above 60 on both daily and weekly charts. The analyst identifies a demand zone at ₹1,040- ₹1,060 and a supply zone near ₹1,160- ₹1,180 as momentum builds.